Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
出版年份 2012 全文链接
标题
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
作者
关键词
-
出版物
AIDS
Volume 27, Issue 6, Pages 939-950
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2012-12-05
DOI
10.1097/qad.0b013e32835cee6e
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
- (2013) Eric S. Daar ANNALS OF INTERNAL MEDICINE
- Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients
- (2012) Calvin J. Cohen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiretroviral Treatment of Adult HIV Infection
- (2012) Melanie A. Thompson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness
- (2011) Rima Kulkarni et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies
- (2011) Laurence Rimsky et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations
- (2011) H.-T. Xu et al. JOURNAL OF VIROLOGY
- Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1
- (2011) Z. Hu et al. JOURNAL OF VIROLOGY
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
- (2011) Calvin J Cohen et al. LANCET
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
- (2011) Jean-Michel Molina et al. LANCET
- Statistical Methods in Recent HIV Noninferiority Trials: Reanalysis of 11 Trials
- (2011) Philippe Flandre PLoS One
- The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study
- (2010) I. Davidson et al. ANTIVIRAL RESEARCH
- Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study
- (2010) Juan Sierra-Madero et al. HIV CLINICAL TRIALS
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
- (2009) H. Azijn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels
- (2009) Andrew Hill et al. HIV CLINICAL TRIALS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started